Lentivirus Vector Rhiv7-Shi-Tar-Ccr5Rz-Transduced Hematopoietic Stem/Progenitor Cells
Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
AIDS Malignancy Consortiumgene_therapyPhase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 81/ 100
Competitive context
35 Active assets in the Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide City of Hope Medical Center | Phase 2 | BB |
ETOPOSIDE Alliance for Clinical Trials in Oncology | Phase 4 | BB |
DEXAMETHASONE Zhengzhou University | Phase 4 | BB |
(+)-VINCRISTINE City of Hope Medical Center | Phase 2 | BB |
Inno-206 City of Hope Medical Center | Phase 2 | BB |
View all 50 →
Same molecule, other indications
Lentivirus Vector Rhiv7-Shi-Tar-Ccr5Rz-Transduced Hematopoietic Stem/Progenitor Cells is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →